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ABSTRACT

Malek, Kotiba. M.S. Department of Chemistry, Wright State University, 2018. RedoxActive Silver N-heterocyclic Carbene Complexes: A Dual Targeting Anti-Bacterial Drug

Bacterial resistance to current β-lactam antibiotics necessitates new therapeutic
approaches. Silver-based drugs offer a promising alternative because of their antibacterial
properties and minimal bacterial resistance. However, many silver-based antibacterial
drugs rapidly release silver ions, limiting the bioavailability of silver ions for a longer
period of time. Recently, N-heterocyclic carbenes (NHC) containing silver complexes
have become a popular subject of research due to their versatility and the slow release of
silver ions under biological conditions. To further enhance the efficacy of silver-NHC
drugs, we fused redox-active substituents such as naphthoquinone and ferrocenes to
NHCs. Both naphthoquinone and ferrocenes have been shown to increase reactive
oxygen species (ROS) under biological conditions that may augment the antibacterial
action of redox-active silver-NHC complexes. Herein, we report synthesis and
characterization of several redox-active silver-NHC complexes, 1-(ferrocenylmethyl)-3mesityl-imidazol-2-ylidene

silver

chloride

[(2)AgCl]

(compound

6),

1,3-di

(ferrocenylmethyl)imidazol-2-ylidene silver chloride [(3)AgCl] (compound 7), bis (1benzyl-3-mesitylimidazol-2-ylidene) silver chloride [(1)2Ag][Cl], (compound 9), Bis (1(ferrocenylmethyl)-3-mesityl-imidazol-2-ylidene) silver chloride [(2)2Ag][Cl] (compound
10), Bis (1,3 di(ferrocenylmethyl)imidazole-2-ylidene) silver chloride [(3)2Ag][Cl]
iii

(compound 11), and bis (1,3-dimesityl-4,5-naphthoquino-imidazol-2-ylidene) silver
chloride [(4)2Ag][Cl] (compound 12). Complexes were identified and confirmed via
various analytical techniques, including 1H NMR, 13C NMR, infrared spectroscopy, UVvis spectroscopy, and single crystal X-ray crystallography.
A series of cyclic and differential pulse voltammetry experiments were conducted
on the complexes to investigate their electrochemical properties. Complexes [(2)AgCl],
[(3)AgCl], [(2)2Ag][Cl], [(2)2Ag][Cl], [(3)2Ag][Cl], and [(4)2Ag][Cl] exhibited redox
activity attributed to the presence of ferrocene and naphthoquinone moiety. Their
antibacterial properties were tested against gram-negative bacterial strains (Escherichia
coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa) and showed excellent
antibacterial properties that are comparable to previously reported silver-NHC
complexes. All silver-NHC complexes detailed in this report exhibit MIC and MBC
values in the range of 2-12.5 µg/mL. Further mechanistic studies are necessary to
elucidate the manner in which these complexes affect bacterial cells.
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Background
N-Heterocyclic Carbenes (NHCs)
N-heterocyclic carbenes (NHC) are cyclic compounds consisting of a carbene
carbon and at least one nitrogen atom within the ring structure (Figure 1).1,2 After the
initial discovery, NHCs were often considered too reactive and unstable for isolation due
to their incomplete electron octet and coordinative unsaturation at the carbon atom. Thus,
multiple attempts to isolate and characterize NHCs dating back to 1830s were deemed
unsuccessful.3 However, Wanzlick4,5 revisited the field in the early 1960s, investigating
the reactivity and stability of NHCs. This paved the way for synthesis of the first NHC
transition metal complexes of chromium and mercury by Ofele6 and Wanzlick7 in 1968.
The following decade saw minimal research in the area, however, and it was not until the
successful isolation of the first stable crystalline NHC, 1,3-diamantylimidazole-2-yidene,
by Arduengo8 in 1991 that the chemistry of NHCs began to receive widespread attention.

Figure 1. General structure of NHC
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Easy synthesis and exceptional stability of the first NHC sparked a wide range of
experimental and theoretical studies, in which numerous NHCs were synthesized and
investigated.9 While the compounds have since become popular in various disciplines,
including polymer chemistry10, coordination chemistry of transition metals11, and
optoelectronics12, they have been used most commonly as ligands on transition metals for
homogeneous catalysis.13 Recently, NHCs have proven useful in medicinal
applications,14 as their versatility and stability allows them to serve as ligands on various
transition metals for therapeutic applications.9, 15
The rise in the use of N-heterocyclic carbenes for a variety of applications stems
from their stability and versatility.16 N-heterocyclic carbenes are strong -donating
ligands, capable of binding strongly to transition metals. Moreover, the nitrogen atoms
render this bond more stable than that of tri-alkyl/aryl phosphines.16 The electronwithdrawing nature of nitrogen, coupled with its p-electron donating property, stabilize
the NHC both by lowering the energy of the s-orbital, and by donating electron density
into the carbene’s empty p-orbital (Figure 2).17 Furthermore, NHCs were once
considered only sigma donors, recent theoretical and structural analysis have revealed
significant π-backbonding from the metal center to the Ccarbene atom of the NHC, further
contributing to its stability (Figure 3).18, 19

Figure 2. Resonance structures of diamine NHCs.
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Figure 3. Representation of -backbonding from metal center to NHC.

In addition to their stability, NHC complexes also boast tremendous versatility,
further contributing to their widespread use. This latter characteristic stems mainly from
their structural diversity, as NHCs can be substituted with an array of functional groups at
various positions, which in turn influence their lipophilicity,20 stability,21 and solubility of
various complexes.22 For instance, kinetic stabilization can be achieved by the addition of
steric and bulky substituents on the nitrogen atom, while electronic stabilization can be
obtained by the addition of aromatic substituents to the backbone. 23 Finally, redox
activity can be achieved by the addition of redox-active components either to the nitrogen
atom or the backbone. The ease with which NHCs can be fine-tuned to suit various uses
is another reason that these compounds are becoming a staple molecule in chemistry.24
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Silver as an Antimicrobial
Silver has long served as an antimicrobial agent (Figure 4).25 Its use dates back to
ancient times, when people stored their water in silver vessels to prevent microbial
contamination.25,26 Around 700 A.C.E., it came into vogue as a treatment for burns and
wounds.27 Much later, in the nineteenth century, doctors began using silver to prevent
contagious diseases. Notable examples include Dr. Marion Sims, who introduced silver
wires in surgery,28 and Dr. Carl Crede, a German gynecologist who began applying 2%
silver nitrate solution to eyes of newborns to prevent infection.29

Figure 4. Medicinal uses of silver throughout history.

Although Alexander Fleming’s 1928 discovery of the first β-lactam antibiotic27
(Penicillin) revolutionized medicine, silver continued to be used as an antimicrobial. It
was only in the 1940s, with the mass production and distribution of Penicillin to the
4

public, that the use of silver proved superfluous.29 Penicillin and its derivatives were
highly effective at first, and Penicillin hailed worldwide as a miracle drug, able to treat
many infectious diseases. Unfortunately, various cases of bacterial resistance soon
arose.30 This alarming development spurred intense research into alternative antibacterial
drugs. Silver ions reentered the medical field in the form of silver sulfadiazine (Figure 5)
in 1968.31 Silver sulfadiazine, discovered by Dr. Charles Fox,31 is a silver-based
antimicrobial agent that is effective against both gram-negative and gram-positive
bacteria. It is commercially available as Silvadene

®

cream 1% and is used in hospitals

worldwide to treat burns. It still remains the gold standard for silver-based antimicrobials.
Silver has also been incorporated in wound dressings in nanocrystalline forms, a practice
that helps sustain the release of silver to wound sites and increase the dressing’s
antimicrobial power.27 Such dressings have shown to be effective in the treatment of leg
ulcers and burn wounds.32

Figure 5. Silver Sulfadiazine Structure.

While reports of bacterial resistance towards silver have been rare, one study has
shown unprecedent silver resistance by two strains of bacteria namely Klebsiella
pneumonia and Enterobacter cloacae.33 These two organisms have shown to be capable
of growth in the presence of high concentrations of silver ions.33 Further investigation of
5

this strain has revealed that it carries a plasmid pMG101 that is responsible for encoding
two efflux pumps (SiICBA and SiIP).33, 34 As a result, the strain is able to expel silver
ions and prevent any subsequent damage to the bacterial cell.34
An additional (and crucial) advantage of silver as an antimicrobial agent is that it
is relatively non-toxic to humans in small doses; in fact, a small amount of silver (2.43
mg/mL) can be found in an average human body.35 However, long and excessive
exposure to elemental silver has been known to cause a rare cosmetic side effect.36 This
condition is called argyria, consists of an irreversible gray-blue discoloration of the
skin.37 In addition, toxicity studies have shown that high levels of silver in the circulatory
system may affect the growth of connective tissue cells,38 bone marrow,39 and epidermal
cells40, by inhibiting cellular respiration.41
Though silver’s widespread use as an antimicrobial agent dates back to the 20th
century, silver ions’ mode of action is not yet clearly understood. However, various
studies have attempted to shed light on the mechanism of action and many pathways have
been proposed. For instance, silver ions may cause destruction of the peptidoglycan cell
wall by interacting with the major proteins and enzymes responsible for cell wall
synthesis.42 One study found that a loss of cell wall integrity was observed in yeast C.
albicans when the silver cation interacted with the enzyme phosphomannose isomerase,
an integral enzyme for cell wall synthesis.43 Furthermore, when silver cations enter the
cell wall and the cytoplasm of bacteria, they have been shown to negatively affect
metabolism and cell respiration, while also damaging DNA and thereby preventing
bacterial replication.42 Yet another study revealed the effect of silver ions in the
generation of reactive oxygen species (ROS).44 The study also demonstrated that silver
6

ions are capable of generating superoxide radicals by damaging certain bacterial
respiratory enzymes.44 The increase in ROS production can trigger a stress response and
the activation of various apoptotic mechanism leading to bacteria death.44

Silver N-Heterocyclic Carbene Complexes
The synthesis of the first silver NHC complex was reported in 1993 by
Arduengo.45 The synthesis utilized a free carbene route (Scheme 1); however, due to the
difficulty of generating free carbenes, as well as their sensitivity to various environmental
factors, such as moisture and heat,46 other approaches were explored.47 This led to the
most common method that is used for generation of silver-NHC complexes, the in situ
deprotonation of imidazolium salt utilizing a basic silver precursor. Various bases have
been used for this reaction, including silver carbonate and silver acetate,44 but silver
oxide (Ag2O) has been the most commonly used.47

Scheme 1. Synthesis of first silver NHC complex.

The first usage of silver oxide as a base to synthesize silver NHC complexes is
credited to Lin et al.,48 who synthesized 1,3 diethylbenzimidazole-2-ylidine (Scheme 2).
The use of silver oxide in the synthesis of silver NHC complexes offers many
advantages: the reaction is easier to conduct, it can be carried at ambient conditions, and
7

it can accommodate a variety of organic solvents.49 Thus, silver oxide is the preferred
base for the generation of silver-NHC complexes.

Scheme 2. Synthesis of first silver NHC complex using Ag2O as a base.

The parameters that affect the aforementioned reaction include the equivalence of
silver compared to the imidazolium salt, the source of silver used, solvent, and the
reaction temperature.46 Various coordination numbers have been reported for silver-NHC
complexes, two being the most common, followed by four, and rarely we encounter silver
NHCs with coordination number of six.50
The diversity of silver(I)-NHC structures and silver ion’s antibacterial properties
facilitated the Young group for synthesis of the first antibacterial silver-NHC complexes
in 2004 (Figure 6).51 These complexes were tested against various bacterial strains
including Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus and
their minimum inhibitory concentration showed antibacterial properties comparable to
silver nitrate MIC value range of 1-3 µg/mL.52
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Figure 6. Silver NHC complexes synthesized by Young’s group.51

This study led a surge of research and a library of silver-NHC complexes with
antibacterial properties were synthesized and studied by various research groups.24
Taking advantage of NHCs’ versatility, complexes of varying structures and physical
properties were synthesized, and their antimicrobial properties tested against various
strains of bacteria.24

9

Introduction
The use of silver as an antimicrobial agent can be traced to ancient times, when it
was one of the few drugs capable of healing infections, burns, and wounds, as well as
preventing contagious diseases.53 Silver in the form of silver nitrate was then used as an
antiseptic in wound care for more than 200 years.54 Its use in medicine, however,
diminished with the introduction of -lactam antibiotics in the 1940s.27 While the mass
production of penicillin and its derivatives was highly effective at first, bacterial
resistance towards such antibiotics soon began to emerge.27 This development prompted a
renewed interest in silver as an antimicrobial agent; it was reintroduced into the field with
Fox’s 1968 discovery of silver sulfadiazine (Silvadene®).31
Silver sulfadiazine is a silver antimicrobial agent that is currently considered the
gold standard for silver-based antimicrobials, used in hospitals worldwide to treat
burns.31 Moreover, bacterial resistance to silver is extremely rare, and the substance poses
no threat to humans (except for a very uncommon skin condition called argyria, which
only occurs after prolonged and excessive exposure).55 Despite their advantages, the use
of silver nitrate, silver sulfadiazine, and other related silver compounds were limited as
they are exclusively targeted for external applications due to the fact that they are water
insoluble.56,57
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However, recent research has focused on the discovery of new and more effective
silver-based antibacterial compounds and, in 2004, Young’s51 group reported silver(I) Nheterocyclic carbene complexes as a new class of antibiotics. N-heterocyclic carbenes
(NHC) form strong M−Ccarbene bonds that are far more stable than most phosphines due to
their increased σ-donation, as well as π-back-donation from metal to the carbene
carbon.58,59,60 This allows for a slower release of silver ions, resulting in an increased
exposure time that disrupts cell wall synthesis and prevents bacterial growth.61 This
difference renders silver(I)-NHC complexes more effective against bacterial reinfection
than traditional silver-based compounds. Moreover, NHCs can be easily modified to
accommodate various substituents, such as caffeine62 and chlorine63 amongst many
others, allowing for further modification of bioactivity and bioavailability. For instance,
the electron-withdrawing chlorine groups have been shown to increase the stability of
silver-NHC complexes in a water medium from a couple of hours to 17 weeks,63 while
the use of caffeine (a xanthine derivative) as the NHC backbone generates a
biocompatible complex, since xanthines are used medicinally and have low toxicity to
humans.62 These properties suggest that silver(I)-NHCs may hold great promise in the
field of antibacterial research.
The N-heterocyclic carbene was first reported in the 1960s by Öfele6 and
Wanzlick7, but it was only in the early 1990s, after the isolation of the first stable carbene
by Arduengo,45 that its use became more common. This discovery led to important
developments in the coordination chemistry of NHCs.11 Numerous metal-NHC
complexes have since been prepared and used as homogeneous catalysts13 in
organometallic transformations13 and, more recently, the use of NHC ligands has become
11

prevalent in biological applications.64 The stability and versatility of these ligands allows
them to serve as metal carriers for transition metals such as copper, gold, and silver in
biological media.14
Building on this foundation, we synthesized several silver-NHC complexes fused
with ferrocene and naphthoquinone substituents. Ferrocene is an organometallic
compound that is capable of undergoing one-electron oxidation to form a ferrocenium
cation, which then goes through a one-electron reduction to regenerate ferrocene.65
Similarly, naphthoquinone, a redox-active moiety that is characterized by the presence of
two carbonyl groups, exhibits multiple reversible redox-active capabilities.66
The reversible redox-active properties of ferrocene and naphthoquinone in
biological media have proven effective against various diseases, including cancer.66 The
redox activity increases reactive oxygen species (ROS), causing oxidative stress in cells
and leading to cell proliferation inhibition and even cell death.66,67,68 The accumulation of
highly reactive ROS such as hydrogen peroxide (H2O2) and O2.- leads to oxidative
damage on biomolecules such as proteins, lipids, and nucleic acid and further promotes
the activation of programmed cell death (PCD).69

12

Figure 7. Combined dual targeting approach.

We hypothesized that an NHC complex that makes use of both redox-active
substituents and the antimicrobial properties of silver could synergistically inhibit
bacterial growth (Figure 7). To this end, a dual targeting drug with the ability to inhibit
bacterial growth through multiple pathways is an appealing prospect in drug discovery,
one

that

could

open

the

door
13

to

future

antibacterial

drugs.

Experimental Section
General Considerations: All synthetic procedures were executed under a nitrogen
atmosphere glove box (Inert Glove Box System). All glasswares were subjected to heat at
110 °C for 12 h before use. The compounds: 1,3-dimesitylnapthoquinimidazolium
chloride, 4, [4H][Cl],70 1-(benzyl)-3-(2,4,6-trimethylphenyl) imidazolium chloride,71,
1,[1H][Cl] 1,3-di(ferrocenylmethyl)imidazolum iodide,72 and 1-(ferrocenylmethy)-3mesityl-limidazolium iodide73 were prepared according to the literature procedures.
Solvents (CH2Cl2, Et2O, THF, and toluene) were dried with a solvent purification system
(Inert Innovative Technology, Inc), degassed using three consecutive freeze-pump-thaw
cycles and stored over 4 Å molecular sieves in the glove box. The NMR solvents: CDCl3
(99.9%) and MeOD (99.8%) were purchased from Acros Laboratories, dried over 4 Å
molecular sieves and stored in the glove box prior to use. All other chemicals were
purchased commercially and used as received. UV-vis spectra were achieved at room
temperature with a Varian Cary 50 Bio UV-vis spectrophotometer. Molar absorptivity for
compounds [(2)AgCl], [(3)AgCl], [(2)2Ag][Cl], [(3)2Ag][Cl], and [(4)2Ag][Cl] were
reported in M−1 cm−1. 1H and

13

C NMR spectra were recorded on Bruker 300 MHz

spectrometer. Spectra were referenced to the residual solvent as an internal standard, for
1

H NMR: CDCl3, 7.26 ppm and 13C NMR 77.16 ppm and for 1H NMR: MeOD, 3.31 ppm

and

13

C NMR 49.15 ppm. Electroanalytical assessments were performed using a
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CHI620E electrochemical workstation using a silver wire quasi-reference electrode, a
platinum disk working electrode and a Pt wire auxiliary electrode in a gas tight threeelectrode cell under a nitrogen atmosphere. The measurements were performed using 1.0
mM of the analyte in dry DMSO with 0.1 M [N(nBu)4][PF6] as the electrolyte and
decamethylferrocene (Fc*) as the internal standard for complexes [(2)AgCl], [(3)AgCl],
[(2)2Ag][Cl], [(3)2Ag][Cl], and ferrocene (Fc) as the internal standard for complex
[(4)2Ag][Cl]. Differential pulse voltammetry measurements were performed with 100 mV
pulse amplitudes and 2 mV data intervals. All potentials recorded herein were calculated
by differential pulse voltammetry at 100 mVs-1 scan rates and referenced to a saturated
calomel electrode (SCE) by shifting decamethylferrocene+ to −0.030 (DMSO) and by
shifting ferrocene + to 0.435 V (DMSO).74

Synthesis of Imidazolium Chloride Salts

1-(Ferrocenylmethyl)-3-mesityl-imidazolium

chloride,

(2)[H][Cl],

2.

To

an

Erlenmeyer flask equipped with stir bar and 75 mL MeOH, 1-(ferrocenylmethyl)-3mesityl-imidazolium iodide (0.780 g, 1.52 mmol) was added with amberlite IRA-400
chloride ion exchange resin (7.80 g). The resulting mixture was stirred for 1 h at room
temperature. The resin was filtered and washed with methanol and the combined filtrates
were charged with a fresh resin (7.80 g) and stirred for 1 h at room temperature. This
process was repeated two times. The final filtrate was dried under reduced pressure. The
dried yellow residue was dissolved in minimum amount of CH2Cl2 and product was
precipitated with 15 mL Et2O producing a yellow solid. Yield: 0.621 g, 97 %. 1H NMR
(δ, CDCl3, 300 MHz): δ 10.97 (s, 1H), 7.50 (s, 1H), 7.03 (s, 1H), 6.95 (s, 2H), 5.57 (s,
15

2H), 4.51 (s, 2H), 4.27-4.24 (d, 7H), 2.30 (s, 3H), 2.02 (s, 6H).13C NMR (δ , CDCl3, 75
MHz): δ 141.18, 138.34, 134.23, 130.90, 129.88, 122.83, 121.98, 79.42, 69.71, 69.40,
50.15, 21.12, 17.81.
1,3-di (ferrocenylmethyl)imidazolium chloride, (3)[H][Cl], 3. To an Erlenmeyer flask
equipped with stir bar and 75 mL methanol, 1, 3-di (ferrocenylmethyl)imidazolum iodide
(0.550 g, 0.928 mmol) was added with amberlite IRA-400 chloride ion exchange resin
(5.50 g). The resulting mixture was allowed to stir for 1 h at room temperature. The resin
was filtered and washed with methanol and the combined filtrates were charged with a
fresh resin (5.50 g) and stirred for 1 h at room temperature. This process was repeated
two times. The final filtrate was dried under reduced pressure. The dried yellow residue
was dissolved in minimum amount of CH2Cl2 and product was precipitated with 15 mL
Et2O producing a yellow solid. Yield: 0.441 g, 95 %. 1H NMR (δ, CDCl3, 300 MHz): δ
11.23 (s, 1H), 6.89 (s, 2H), 5.29 (s, 4H), 4.28 (s, 4H), 4.23 (s, 14H).13C NMR (δ, CDCl3,
75 MHz): δ 120.38, 78.81, 69.88, 69.71, 69.37, 50.18.

Synthesis of Heterolyptic Imidazole-2-Ylidene Silver Chlorides70

1-(ferrocenylmethyl)-3-mesityl-imidazol-2-ylidene silver chloride, [(2)AgCl], 6. A 10
mL vial with stir bar was charged with 1-(ferrocenylmethyl)-3-mesityl-imidazolium
chloride (0.150 g, 0.356 mmol, 1 eq), silver oxide (0.061 g, 0.267 mmol, 0.75 eq), and
4.0 mL of dry CH2Cl2. The mixture was stirred at room temperature for 24 h, which
resulted in a solution with yellow suspension. The heterogeneous mixture was filtered
through a plug of celite into a pre-weighed vial and the filtrate was concentrated to a
minimum amount (~ 2 mL) and the compound was precipitated with 15 mL of Et 2O. The
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precipitate was washed with 3 ×10 mL of Et2O to yield a yellow solid. Yield: 0.125 g,
89 %. 1H NMR (δ, CDCl3, 300 MHz): δ 7.08 (s, 1H), 6.93 (s, 2H), 6.85 (s, 1H), 5.15 (s,
2H), 4.33 (s, 2H), 4.25-4.23 (m, 7H), 2.32 (s, 3H), 1.93 (s, 6H).13C NMR (δ, CDCl3, 75
MHz): δ 139.68, 135.54, 134.82, 129.58, 122.67, 122.57, 120.45, 81.57, 69.34, 69.16,
52.14, 21.19, 17.84.
1,3-di (ferrocenylmethyl)imidazol-2-ylidene silver chloride, [(3)AgCl], 7. A 10 mL
vial with stir bar was charged with 1,3-di (ferrocenylmethyl)imidazolum chloride (0.145
g, 0.289 mmol, 1 eq), silver oxide (0.050 g, 0.217 mmol, 0.75 eq), and 4.0 mL of dry
CH2Cl2. The mixture was stirred at room temperature for 24 h, which resulted in a
solution with yellow suspension. The heterogeneous mixture was filtered through a plug
of celite into a pre-weighed vial and the filtrate was concentrated to a minimum amount
(~ 2 mL) and the compound was precipitated with 15 mL of Et2O. The precipitate was
washed with 3 ×10 mL of Et2O to yield a yellow solid. Yield: 0.112 g, 85 %. 1H NMR
(δ, CDCl3, 300 MHz): δ 6.81 (s, 2H), 4.96 (s, 4H), 4.28-4.27 (m, 4H), 4.20-4.19 (m,
14H).13C NMR (δ, CDCl3, 75 MHz): δ 120.30, 81.55, 69.30, 69.27, 69.09, 52.07.

Synthesis of Homoleptic Imidazole-2-Ylidene Silver Chlorides
Bis (1-benzyl-3-mesitylimidazol-2-ylidene) silver chloride, [(1)2Ag][Cl], 9. In a 10 mL
vile equipped with a stir bar, 1-(benzyl)-3-(2,4,6-trimethylphenyl) imidazolium chloride
(0.120 g, 0.384 mmol, 1 eq) and Sodium bis(trimethylsilyl)amide (0.077 g, 0.422 mmol,
1.1 eq) were mixed in toluene. After 2 h, the yellow solution was filtered through a plug
of celite into a vile containing AgCl (0.0247g, 0.173 mmol, 0.45 eq). The mixture was
stirred for 24 h. The resulting solution was filtered through a plug of celite and dried
under vacuum. The brown residue was dissolved in minimum amount (~ 2 mL) of
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CH2Cl2 and the product was precipitated with 15 mL Et2O and further washed with 3 ×
10 mL Et2O to produce a white solid. Yield: 0.75 g, 78%. 1H NMR (δ, CDCl3, 300 MHz):
δ 7.47 (m, 2H), 7.30-7.27 (m, 6H), 7.13-7.12 (m, 4H), 6.88 (s, 2H), 6.84 (s, 4H), 5.28 (s,
4H), 2.29 (s, 6H), 1.77 (s, 12H).13C NMR (δ, CDCl3, 75 MHz): δ 139.29, 136.71, 135.75,
134.98, 129.27, 129.02, 128.39, 127.62, 122.76, 55.26, 21.23, 17.73.

Bis (1-(ferrocenylmethyl)-3-mesityl-imidazol-2-ylidene) silver chloride, [(2)2Ag][Cl],
10. In a 10 mL vial equipped with a stir bar was added 1-(ferrocenylmethyl)-3-mesitylimidazolium chloride (0.142 g, 0.337 mmol, 1 eq), sodium bis(trimethylsilyl)amide
(0.0681 g, 0.371 mmol, 1.1 eq), and 5 mL of toluene. After 2 h stir at rt, the yellow
solution was filtered through a plug of celite into a vile containing AgCl (0.0217 g, 0.152
mmol, 0.45 eq). The mixture was stirred for 24 h. The resulting solution was filtered
through a plug of celite and dried under vacuum. The brown residue was dissolved in
minimum amount (~ 2 mL) of CH2Cl2 and the product was precipitated with 15 mL Et2O
and further washed with 3 ×10 mL Et2O to produce a yellow solid. Yield: 0.96 g, 82%.
1

H NMR (δ, CDCl3, 300 MHz): δ 7.55-7.54 (m, 2H), 6.89 (s, 4H), 6.89-6.84 (m, 2H),

5.13 (s, 4H), 4.21-4.16 (m, 18H), 2.36 (s, 6H), 1.77 (s, 12H).13C NMR (δ, CDCl3, 75
MHz): δ 139.20, 135.87, 134.99, 129.58, 129.32, 122.48, 122.41, 122.31, 83.02, 69.18,
68.92, 68.67, 51.49, 21.33, 17.78.
Bis (1,3 di (ferrocenylmethyl)imidazole-2-ylidene) silver chloride, [(3)2Ag][Cl], 11. In
a 10 mL vile equipped with a stir bar, 1,3 di (ferrocenylmethyl)imidazolum chloride
(0.200 g, 0.400 mmol, 1 eq) and Sodium bis(trimethylsilyl)amide (0.0806 g, 0.440 mmol,
1.1 eq) were mixed in toluene. After 2 h, the yellow solution was filtered through a plug
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of celite into a vile containing AgCl (0.0257 g, 0.180 mmol, 0.45 eq). The mixture was
stirred for 24 h. The resulting solution was filtered through a plug of celite and dried
under vacuum. The brown residue was dissolved in minimum amount (~ 2 mL) of
CH2Cl2 and the product was precipitated with 15 mL Et2O and further washed with 3 ×
10 mL Et2O to produce a yellow solid. Yield: 0.120 g, 60%. 1H NMR (δ, CDCl3, 300
MHz): δ 6.83 (s, 4H), 4.99 (s, 8H), 4.28-4.27 (m, 8H), 4.20-4.19 (28H).
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C NMR (δ,

CDCl3, 75 MHz): δ 120.32, 81.63, 69.27, 69.10, 52.04.
Bis (1,3-dimesityl-4,5-naphthoquino-imidazol-2-ylidene) silver chloride, [(4)2Ag][Cl],
12. In a 10 mL vile equipped with a stir bar, 1,3-dimesitylnaphthoquinimidazolium
chloride (0.150 g, 0.318 mmol, 1 eq) and Sodium bis(trimethylsilyl)amide (0.064 g,
0.349 mmol, 1.1 eq) were mixed in toluene. After 24 h, the yellow solution was filtered
through a plug of celite into a vile containing AgCl (0.020 g, 0.14 mmol, 0.45 eq). The
mixture was stirred for 24 h. The resulting solution was filtered through a plug of celite
and dried under vacuum. The brown residue was washed with 10 mL of toluene followed
by 3 ×10 mL Et2O.The solid was dissolved in minimum MeOH, filtered through a celite
and dried under vacuum to produce a green solid. Yield: 0.09 g, 64%. 1H NMR (δ,
CD3OD, 300 MHz): δ 8.08-8.06 (m, 4H), 7.84−7.81 (m, 4H), 7.10 (s, 8H), 2.50 (s, 12H),
1.77 (s, 24H).13C NMR (δ, CD3OD, 75 MHz): δ 175.92, 141.69, 135.93, 135.63, 135.00,
134.23, 134.15, 133.77, 130.68, 128.05, 21.53, 17.87. IR (cm−1): 1683 (MeOH).

In Vitro Antimicrobial Activity
Using an agar dilution procedure,75 the antimicrobial activity of the new silver-NHC
complexes were investigated. The minimal inhibitory concentrations (MICs) and the
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minimal bactericidal concentrations (MBCs) for complexes 1-12 were tested against
standard bacterial strains (E. Coli, P. aeruginosa, K. pneumoniae). Bacteria from fresh
overnight plates were suspended in standard Muller-Hinton broth (M-H) to an optical
density at 600 nm (OD600) of 0.13. The bacteria were diluted in the broth to a
concentration of 105 CFU/mL. The stock solutions of all complexes were prepared in
DMSO (25%). The concentrations of the tested complexes were 1, 2, 4, 5, 8, 10, 12.5, 25,
50, 60, 70, 80, 90 and 100 µg/mL. The MIC was the lowest concentrations, at which
visible growth is absent after incubation of the plate for 24 h at 37 °C. The MBC for all
complexes were determined by plating all of the clear wells of the MIC experiments on
TSA agar plates, incubating the plates overnight at 37 °C, and observing the
concentration at which there were no visible colony growth. Silver nitrate was used as the
control.

A

total

of

3

trials

were
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conducted

for

each

experiment.

Results and Discussion

Figure 8. Silver-NHC complexes studied.

Synthesis and Characterization
Using a modified literature procedure70, a neutrally charged silver-NHC complex
[(2)AgCl] (6) and [(3)AgCl] (7) were synthesized (Scheme 3).
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Scheme 3. Preparation of complexes 6 and 7.

Complex [(2)AgCl] (6) and [(3)AgCl] (7) were prepared by treating 1 equivalence of
compound (2)[H][Cl] and (3)[H][Cl], respectively, with 0.75 Ag2O and molecular sieves
for 24 h at room temperature in CH2Cl2. At the end of 24 h stir, the crude mixture was
subjected to simple filtration to yield crude solids of [(2)AgCl] (6) and [(3)AgCl] (7). The
obtained crude products were dissolved in a minimum amount of CH2Cl2 and precipitated
with Et2O to yield microcrystals of [(2)AgCl] (6) and [(3)AgCl] (7). Proton NMR
spectral analyses of complex [(2)AgCl] (6) and [(3)AgCl] (7)

in CDCl3 proved

consistent with the molecular structure. Specifically, the absence of the hydrogen
attached to Ccarbene in the 1H NMR of [(2)AgCl] (6) and [(3)AgCl] (7), corroborates the
formation of silver-carbene bond at the carbene carbon. 1H NMR analysis of complex
[(2)AgCl] (6) displayed mesityl hydrogens (ortho-CH3 and para-CH3) at 1.93 and 2.32
ppm, respectively. The signals between 4.23-4.33 ppm represents the 9 hydrogens
attached to the ferrocene unit. The benzylic CH2 hydrogens were observed at 5.15 ppm.
The signals at 6.85 and 7.08 ppm each correspond to C2 and C3 imidazole hydrogens.
The two aromatic mesityl hydrogens, are represented by a signal at 6.93 ppm. Proton
NMR spectrum of compound [(3)AgCl] (7) reveals signals between 4.19-4.28 ppm which
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corresponds to 18 hydrogens attached to the two ferrocene units. The symmetrical
benzylic CH2 hydrogens is represented by a single peak at 4.96 ppm. The two hydrogens
at C2 and C3 of the imidazole unit is represented by a single peak at 6.81 ppm, consistent
with C2 symmetry is present due to the two ferrocene substituents, in contrast to complex
[(2)AgCl] (6), where the hydrogens at C2 and C3 is presented by two peaks validating the
asymmetric nature of the complex.

Figure 9. 1 H NMR spectrum (300 MHz, CDCl3) of compound 6, [(2)AgCl].

The homoleptic complexes 9-12 were synthesized using a modified literature procedure76
by in situ generation of free carbene of the corresponding imidazolium salts 1-4 using
NaN(SiMe3)2, followed by immediate treatment with 0.40 equivalents of AgCl in toluene
(Scheme 4).
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Scheme 4. Preparation of the homoleptic complexes 9-12.

The insoluble nature of complexes 9-12 in toluene allowed for their separation from the
reaction mixture. The complexes were subjected to celite filtration followed by 3 ×10
mL toluene and 3 ×10 mL Et2O washes. Subsequently, complexes 9-11 were dissolved
in minimum amount (~ 2 mL) of CH2Cl2 and precipitated with 10 mL Et2O. while,
complex [(4)2Ag][Cl] (12) was dissolved in MeOH, filtered using celite plug, and dried.
1

H NMR spectral analyses of the homoleptic complexes proved consistent with molecular

structures. The absence of the hydrogen attached to Ccarbene in the 1H NMR of complexes
9–12 proves the formation of silver-carbene bond at the carbene carbon. Complex
[(1)2Ag][Cl] (9) proton NMR (CDCl3) spectrum shows mesityl hydrogens (ortho-CH3
and para-CH3) were observed at 1.77 and 2.36 ppm respectively. The signals between
4.16-4.21 ppm represents the 9 hydrogens attached to the ferrocene unit. The benzylic
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CH2 hydrogens was observed at 5.13 ppm. The signals at 6.85 and 7.54 ppm each
correspond to C2 and C3 imidazole hydrogens. The two aromatic mesityl hydrogens, are
represented by a signal at 6.89 ppm. Complex [(2)2Ag][Cl] (10) 1H NMR (CDCl3)
spectrum reveals signals between 4.19-4.28 ppm which corresponds to the 18 hydrogens
attached to the two ferrocene units. The symmetrical benzylic CH 2 hydrogens is
represented by a single peak at 4.99 ppm. The two hydrogens at C2 and C3 of the
imidazole unit is represented by a single peak at 6.83 ppm proving a symmetry is present
due to the two ferrocene substituents.

1

H NMR (CDCl3) spectrum for complex

[(3)2Ag][Cl] (11) shows mesityl hydrogens (ortho-CH3 and para-CH3) were observed at
1.77 and 2.29 ppm respectively. The benzylic CH2 hydrogens was observed at 5.28 ppm.
The mesityl aromatic hydrogens are represented at 6.84 ppm. Imidazolylidene hydrogens
C2 and C3 appear at 6.88 and 7.47 ppm respectively. The hydrogens of four phenyl
groups are represented in the region 7.10 – 7.30 ppm. Proton NMR spectral analyses of
complex [(4)2Ag][Cl] (12) in MeOD proved consistent with the molecular structure. For
instance, mesityl hydrogens (ortho-CH3) were observed at 1.77 ppm, while mesityl
hydrogens (para-CH3) were observed at 2.50 ppm. The mesityl aromatic hydrogens
appeared at 7.10 ppm, while the naphthoquinone benzene hydrogens appeared within the
7.81-8.09 ppm range. To further confirm the validity of the structure, an IR spectrum of
complex [(4)2Ag][Cl] (12) was obtained in MeOH. The IR spectrum revealed a peak at
1683 cm-1, which is indictive of a carbonyl peak from the naphthoquinone moiety. This
peak is consistent with literature70 and provides additional validation of the complex
synthesized.
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The absence of C–Ag in the

13

C NMR in all the complexes is indictive of fluxional

behavior which is a common phenomenon that is observed with many silver (I)
complexes.77

Figure 10. 13 C NMR spectrum (75 MHz, CDCl3) of compound 6, [(2)AgCl].

To further substantiate the validity of the complexes synthesized, x-ray diffractions of the
heterolytic complexes 6-7 and the homoleptic complexes 9-12 were obtained. For
instance, single crystals of complex [(2)AgCl] (6) were grown by slowly diffusing
hexane into a concentrated CHCl3 solution. Complex [(2)AgCl] (6) has an C1–Ag1–Cl1
angle of 175.84(7) ° and N2–C1–N1angle of 104.4 (2) . The C1–N1 and C2–N1 bond
lengths are 1.355 (3) Å and 1.386 (4) Å, respectively. The Bond length for C1–Ag1 is
2.064 (3) Å and bond length for Ag1–Cl1 is 2.320 (7) Å (Figure 9). The Ag-C bond
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distance of 2.064(3) Å is comparable to those found in other heterolytpic silver NHC
complexes.78

Figure 11. ORTEP diagram of complex 6 drawn using POV-Ray. Thermal ellipsoid plots are drawn at 50%
probability level and hydrogen atoms are omitted for clarity

Similarly, single crystals of [(1)2Ag][Cl] (9) were grown by diffusing methyl tert-butyl
ether into a concentrated CHCl3 solution. Complex 9 has an N1–C1–N2 bond angle of
104.09 (19) Å, C1–Ag1–Cl1 bond angle of 101.06 (6) , and Ag1–Cl1–Ag2 bond angle
of 148.87 (2) . The bond lengths between C1–Ag1 is 2.104 (2) Å, Ag1–Cl1 is 2.8152 (6)
Å, C1–N1is 1.350 (3) Å, Cl1–Ag2 is 2.8754 (6) Å, and N1–C2 is 1.382 (3) Å (Figure
10).
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Figure 12. ORTEP diagram of complex 9 drawn using POV-Ray. Thermal ellipsoid plots are drawn at 50%
probability level and hydrogen atoms are omitted for clarity.

Single crystals for Complex [(2)2Ag][Cl] (10) were grown by diffusing methyl tert-butyl
ether into a concentrated CHCl3 solution. Complex [(2)2Ag][Cl] (10) presented a bond
angle of 165.99 (17)  for C1–Ag1–C4 and a bond angle of 104.3 (4)  for N1–C1–N2.
The bond lengths between Ag1–C1 is 2.089 (4) Å, C1–N1 is 1.346 (6) Å, N1–C2 is 1.389
(6) Å, and C2–C3 is 1.343 (7) Å (Figure 11).
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Figure 13. ORTEP diagram of complex 10 drawn using POV-Ray. Thermal ellipsoid plots are drawn at
50% probability level and hydrogen atoms are omitted for clarity.

Silver-NHC complexes [(2)AgCl] (6), [(3)AgCl] (7), [(2)2Ag][Cl] (10),
[(3)2Ag][Cl] (11), and [(4)2Ag][Cl] (12) were also characterized by ultraviolet-visible
spectroscopy. Complexes 6-7 and 10-11, consisting of ferrocene moiety, displayed an
absorption band at ~ 440 nm. This is consistent with values reported in the literature for
ferrocene containing complexes.61 Complex 10, which contains naphthoquinone moiety,
displayed a low energy π to π* band near the visible region at ~ 340 nm and a high
energy π to π* band at ~ 260 nm. These peaks corresponding to naphthoquinone moiety
are consistent with literature. 79
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Electrochemistry
To analyze the electronic properties of the complexes synthesized, a series of
electrochemical analysis, including cyclic voltammetry (CV) and differential pulse
voltammetry (DPV) were carried out with [N(nBu)4][PF6] in anhydrous dimethyl
sulfoxide (DMSO). Cyclic voltammetry of the redox-active complexes synthesized are
provided in Figure 12, while key data obtained from differential pulse voltammetry for
the complexes are summarized in Table 1. The heterolytic complexes 6-7 and the
homoleptic complex 10-11 that includes a ferrocene substituent, displayed a reversible
one electron oxidation (Fe2+→ Fe3+). One electron oxidation for complex [(2)AgCl] (6)
and [(3)AgCl] (7) were observed at  0.46 V (vs. SCE), whereas the homoleptic
complexes [(2)2Ag][Cl] (10) and [(3)2Ag][Cl] (11), their oxidations were observed at
0.56 and 0.52 V (vs. SCE) respectively.
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Figure 14. Cyclic voltammetry of redox-active complexes

31

Table 1. Electrochemical properties.

COMPOUND

E1/2 (V) DPV

[(2)AgCl], 6

0.47

[(3)AgCl], 7

0.46

[(2)2Ag][Cl], 10

0.56

[(3)2Ag][Cl], 11

0.52

[(4)2Ag][Cl], 12

−0.48a, −1.34b

a

ASSIGNED AS THE FIRST REDUCTION (FORMATION OF SEMIQUINONE RADICAL, NQ·−)

b

ASSIGNED AS THE SECOND REDUCTION (FORMATION OF QUINONE DIANION, NQ2−)

Electrochemical analysis of the redox-active complexes. The potentials were obtained from differential pulse
voltammetry measurement in DMSO using 0.1 M [N(nBu)4]+[PF6]− as the supporting electrolyte, 0.1 mM analyte,
and referenced vs. SCE. For the corresponding cyclic voltammograms and differential pulse voltammograms refer
to the supporting information.

Compound [(4)2Ag][Cl] (12) exhibited cathodic waves that occur in two sequential steps.
The first wave is completely reversible, and the second wave is quasireversible at 0.1 mV
s−1 scan rate. These electrochemical features are attributed to the reduction of the quinone
moiety to first produce the semi-quinone radical (NQ−) at −.48 V and then produce the
quinone dianion (NQ2−) at −1.34 V.
The electrochemical properties of the complexes [(2)AgCl] (6), [(3)AgCl] (7),
[(2)2Ag][Cl] (10), [(3)2Ag][Cl] (11), and [(4)2Ag][Cl] (12) from the series of CV and
DPV conducted, confirms the redox-active potential of the ferrocene and naphthoquinone
substituents that are present in these complexes.
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Antibacterial Activity
After the synthesized complexes were confirmed via analytical techniques and their
redox-activity studied, the in vitro antibacterial properties of these complexes were
investigated. In order to determine the effectiveness of these heterolytic and homoleptic
complexes, minimum inhibitory concentration (MIC) and minimum bacteriostatic
concentrations (MBC) were determined against three gram-negative bacteria ((E. coli, K.
pneumonaie, P.aeruginosa) in Muller-Hinton (M-H) broth (Table 2). Complexes were
dissolved in DMSO and a series of dilutions were prepared followed by 24 h incubation
with the bacterial strain in growth media at 37 °C. The MIC was determined as the lowest
concentrations, at which visible growth is absent. The MBC for all complexes were
determined by plating all of the clear wells of the MIC experiments on TSA agar plates,
incubating the plates overnight at 37 °C, and observing the concentration at which there
were no visible colony growth.
The imidazolium salts 1-4, containing no silver ions, had MIC and MBC values
ranging from 60-100±5 µg/mL. These salts exhibited high MIC and MBC values due to
the absence of the antibacterial silver ions. The heterolytic complexes 5-8 and the
homoleptic complexes 9-12 displayed MIC and MBC values more effective than their
corresponding salts and comparable to silver nitrate—an established antibacterial agent.
The MIC value range for complexes 5-8 was 4-8 µg/mL with the most effective
complexes being complex [(2)AgCl] (6), [(3)AgCl] (7) across all three bacteria. These
complexes also proved to be bactericidal against the bacteria tested with MBC values
range from 2-8 µg/mL. Similarly, the homoleptic complexes 9-12 exhibited antibacterial
properties superior than their corresponding imidazolium salts and comparable to the
33

heterolytic complexes and silver nitrate.

Complexes 9-12 displayed antibacterial

properties with MIC and MBC range of 2-12.5±2 µg/mL.
Overall, these MIC and MBC studies suggests that these complexes appear to be capable
of killing gram-negative bacteria at concentrations comparable to silver NHCs values
obtained the literature.52 For instance, Young’s silver NHCs have MIC values ranging
from 1-8 µg/mL.51 We propose that both the redox-active substituents and silver ions
have contributed to the bacterial growth inhibition. In order to further elucidate on the
mechanism, mechanistic studies and evaluations need to be conducted.
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Table 2. MIC and MBC of the complexes studied in µg/mL.

Species

E. coli

K. pneumonaie

P.aeruginosa

Complexes

MIC

MBC

MIC

MBC

MIC

MBC

(1)[H][Cl], 1

60±5

70±5

80±5

80±5

100±5

100±5

(2)[H][Cl], 2

60±5

80±5

80±5

90±5

80±5

90±5

(3)[H][Cl], 3

60±5

60±5

80±5

90±5

80±5

80±5

(4)[H][Cl], 4

100±5

100±5

80±5

90±5

100±5

100±5

[(1)AgCl], 5

8±2

8±2

5±2

5±2

4±2

5±2

[(2)AgCl], 6

4±2

4±2

5±2

4±2

4±2

4±2

[(3)AgCl], 7

4±2

4±2

4±2

4±2

4±2

4±2

[(4)AgCl], 8

8±2

8±2

4±2

4±2

8±2

5±2

[(1)2Ag][Cl], 9

10±2

12.5±2

10±2

10±2

10±2

12.5±2

[(2)2Ag][Cl], 10

8±2

10±2

8±2

8±2

8±2

8±2

[(3)2Ag][Cl], 11

8±2

8±2

5±2

5±2

4±2

5±2

[(4)2Ag][Cl], 12

8±2

8±2

4±2

4±2

4±2

5±2

AgNO3

2±2

2±2

2±2

2±2

2±2

4±2
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Conclusion
We report the synthesis of six redox-active silver NHC complexes with
antibacterial properties. The heterolytic complexes, [(2)AgCl] and [(3)AgCl], were
prepared by the reaction of their respective imidazolium salts with silver (I) oxide in
dichloromethane;

while

the

homoleptic

complexes,

[(1)2Ag][Cl],

[(2)2Ag][Cl],

[(3)2Ag][Cl], and [(4)2Ag][Cl], were synthesized by a two-step process, which included
the deprotonation of salts followed by silver chloride treatment. All complexes were
confirmed and characterized using elemental analysis and spectroscopic techniques
including,

1

H and

13

Spectroscopy. 1H and

C NMR spectroscopy, infrared spectroscopy, and UV-vis

13

C NMR spectral analyses of the heterolytic and homoleptic

complexes proved consistent with molecular structures. The electronic properties of the
complexes were investigated by cyclic and differential pulse voltammetry. Complexes
with naphthoquinone or ferrocene substituents exhibited redox-active properties
consistent with literature. The antibacterial properties of these complexes were tested
against three standard strains of gram-negative bacteria (E. coli, K. pneumonaie,
P.aeruginosa). All complexes exhibited similar MIC and MBC activities to silver nitrate,
establishing the antibacterial properties of these complexes.
Our future work involves examining and understanding the mechanistic pathway
these redox-active silver-NHC complexes employ to inflict bacterial death. Further, since
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redox-active complexes have shown to cause apoptosis to cancer cells, our
research group is interested in investigating the anticancer properties of these complexes.
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Analytical Data
Electrochemical Analysis

Figure 15. Cyclic Voltammogram of complex 6, [(2)AgCl].

Figure 16. Differential Pulse Voltammogram of Complex 6, [(2)AgCl].
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Figure 17. Cyclic Voltammogram of complex 7, [(3)AgCl].

Figure 18. Differential Pulse Voltammogram of Compound 7, [(3)AgCl].
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Figure 19. Cyclic Voltammogram of complex 10, [(2)2Ag][Cl].

Figure 20. Differential Pulse Voltammogram of Complex 10, [(2)2Ag][Cl].
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Figure 21. Cyclic Voltammogram of complex 11, [(3)2Ag][Cl].

Figure 22. Differential Pulse Voltammogram of Complex 11, [(3)2Ag][Cl].
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Figure 23. Cyclic Voltammogram of complex 12, [(4)2Ag][Cl].

Figure 24. Differential Pulse Voltammogram of Complex 12, [(4)2Ag][Cl].

42

1

H NMR and 13C NMR Spectra

Figure 25. 1 H NMR spectrum (300 MHz, CDCl3) of compound 7, [(3)AgCl].

Figure 26. 13 C NMR spectrum (75 MHz, CDCl3) of compound 7, [(3)AgCl].
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Figure 27. 1 H NMR spectrum (300 MHz, CDCl3) of compound 9, [(1)2Ag][Cl].

Figure 28. 13 C NMR spectrum (75 MHz, CDCl3) of compound 9, [(1)2Ag][Cl].

44

Figure 29. 1 H NMR spectrum (300 MHz, CDCl3) of compound 10, [(2)2Ag][Cl].

Figure 30. 13 C NMR spectrum (75 MHz, CDCl3) of compound 10, [(2)2Ag][Cl].

45

Figure 31. 1 H NMR spectrum (300 MHz, CDCl3) of compound 11, [(3)2Ag][Cl].

Figure 32. 13 C NMR spectrum (75 MHz, CDCl3) of compound 11, [(3)2Ag][Cl].

46

Figure 33. 1 H NMR spectrum (300 MHz, MeOD) of compound 12, [(4)2Ag][Cl].

Figure 34. 13 C NMR spectrum (75 MHz, MeOD) of compound 12, [(4)2Ag][ Cl].

47

UV-Vis Absorption Spectra

Figure 35. Electronic absorption spectra of complex 6 and 7 recorded in DMSO.

Figure 36. Electronic absorption spectra of complexes 10 and 11 recorded in DMSO.

48

Figure 37. Electronic absorption spectra of complex 12, [(4)2Ag][Cl], 12 recorded in DMSO.

49

Infrared Spectroscopy Spectra

Figure 38. IR spectrum of complex 12, [(4)2Ag][Cl] recorded in DMSO.
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